🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseFibrosis regression on GLP-1 — anyone have experience?

Fibrosis regression on GLP-1 — anyone have experience?

PeptideChemSF Sun, Aug 4, 2024 at 9:25 PM 10 replies 1,943 viewsPage 1 of 2
This thread is more than 22 months old. Information may be outdated. Consider searching for more recent discussions.
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Aug 4, 2024 at 9:25 PM#1

Fatty liver on an incidental scan two years ago and nobody followed it up. Now that I am losing weight I would like to know what to re-measure.

What would genuinely help is knowing whether normalised enzymes tell you anything about fibrosis, and what the right follow-up measurement is.

Happy to be told the question itself is wrong.

48 18steve_okc, dave_SLC, FDA_TrackerJim and 45 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
Aug 4, 2024 at 9:52 PM#2
PeptideChemSF said:
Fatty liver on an incidental scan two years ago and nobody followed it up.

NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy. The Phase 2b data for semaglutide showed 59% NASH resolution (vs 17% placebo) with 43% achieving fibrosis improvement[1].

Mechanism: GLP-1R activation reduces hepatic lipogenesis, increases fatty acid oxidation, reduces hepatic inflammation, and may directly reduce hepatic stellate cell activation (fibrosis pathway).

With resmetirom (thyroid hormone receptor agonist) recently approved for NASH, the field is evolving rapidly. Combination approaches (GLP-1 + resmetirom) are being explored.

References:
[1] Newsome PN, et al. N Engl J Med. 2021;384(12):1113-1124.
Last edited: Aug 5, 2024 at 1:52 AM
47 17PharmHunterJen, TomTeleRx, DoseLogDan and 44 others
Reply Quote Save Share Report
pam_columbus
Member
312
1,345
Aug 2024
Columbus, OH
Aug 4, 2024 at 10:19 PM#3
TrialNerd_Beth said:
NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.

ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase 3 ATTAIN trial. NASH resolution was achieved in ~60% of patients[1].

This is relevant to liver and MASH because survodutide's glucagon agonism specifically targets hepatic lipid metabolism — making it potentially the best-in-class agent for NASH/MAFLD comorbid with obesity.

References:
[1] Sanyal AJ, et al. N Engl J Med. 2024.
Last edited: Aug 5, 2024 at 4:19 AM
46 16Dr.LipidDallas, alex_tucson, kevin_tulsa and 43 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
WendyG_ATL
Member
1,023
5,678
Apr 2024
Georgia
Aug 4, 2024 at 10:46 PM#4
PeptideChemSF said:
Fatty liver on an incidental scan two years ago and nobody followed it up.

Same experience, arrived at from the opposite direction.

Last edited: Aug 4, 2024 at 11:46 PM
45 15AttorneyGrant, DebRD_ATL, KristenIndy and 42 others
Reply Quote Save Share Report
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Aug 5, 2024 at 1:14 AM#5

From the other side of the consultation, briefly.

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

Baseline: "Moderate hepatic steatosis, liver span 17.2cm, echogenic texture consistent with fat infiltration"
Month 8: "Mild steatosis, liver span 15.8cm, improved echogenicity"
Month 14: "Minimal to no steatosis, normal liver span 14.5cm, normal echotexture"

My liver literally shrank and de-fattened. The ultrasound tech said she's seen this pattern increasingly in GLP-1 patients and it's remarkable how consistently the fatty liver resolves.

44 14mel_PDX, Dr.AddMedPHL, newstart_MO and 41 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register